ES2173641T3 - Composicion de derivados opiaceos para la fabricacion de medicamentos. - Google Patents

Composicion de derivados opiaceos para la fabricacion de medicamentos.

Info

Publication number
ES2173641T3
ES2173641T3 ES98956656T ES98956656T ES2173641T3 ES 2173641 T3 ES2173641 T3 ES 2173641T3 ES 98956656 T ES98956656 T ES 98956656T ES 98956656 T ES98956656 T ES 98956656T ES 2173641 T3 ES2173641 T3 ES 2173641T3
Authority
ES
Spain
Prior art keywords
patient
antinociceptive
conjugate
vivo
introducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956656T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Application granted granted Critical
Publication of ES2173641T3 publication Critical patent/ES2173641T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Utilización de una composición para la fabricación de un medicamento, constando dicha composición de un derivado de un opiáceo y análogos del mismo, caracterizada porque el derivado contiene un grupo funcional reactivo, que reacciona con grupos amino, grupos hidroxilo o grupos tiol de componentes de la sangre para formar enlaces covalentes estables, seleccionándose dicho grupo funcional reactivo entre N-hidroxi-succinimida, N-hidroxi-sulfo-succinimida y un grupo de maleimida, para aliviar el dolor o proporcionar un efecto analgésico.
ES98956656T 1997-11-07 1998-11-06 Composicion de derivados opiaceos para la fabricacion de medicamentos. Expired - Lifetime ES2173641T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
ES2173641T3 true ES2173641T3 (es) 2002-10-16

Family

ID=22057753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956656T Expired - Lifetime ES2173641T3 (es) 1997-11-07 1998-11-06 Composicion de derivados opiaceos para la fabricacion de medicamentos.

Country Status (9)

Country Link
EP (2) EP1007561B1 (es)
JP (2) JP2001522863A (es)
AT (2) ATE216402T1 (es)
AU (3) AU750387B2 (es)
CA (2) CA2301799C (es)
DE (2) DE69804974T2 (es)
ES (1) ES2173641T3 (es)
IL (1) IL135835A0 (es)
WO (3) WO1999024074A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
CA2291066A1 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
HK1042114B (zh) 1998-10-23 2006-09-29 Amgen K-A, Inc. 与mp1受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1623994A3 (en) * 1999-05-17 2008-07-16 ConjuChem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
BR0010757A (pt) 1999-05-17 2002-02-19 Conjuchem Inc Inibidores de peptìdeo de fusão de longa duração de infecção viral
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
CN1491233A (zh) 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DK1479691T3 (da) 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
WO2004066917A2 (en) 2003-01-17 2004-08-12 Advanced Proteome Therapeutics, Inc Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
CA2564031A1 (en) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US20170158599A1 (en) * 2014-07-18 2017-06-08 Joseph D. Ceccoli Compositions and methods comprising salicylates and polysalicylates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
AU750387B2 (en) 2002-07-18
DE69812727D1 (de) 2003-04-30
EP1007561A2 (en) 2000-06-14
EP1007561B1 (en) 2002-04-17
WO1999024074A2 (en) 1999-05-20
WO1999024076A9 (en) 2000-06-08
DE69804974T2 (de) 2002-11-07
EP1028971A2 (en) 2000-08-23
WO1999024076A3 (en) 1999-08-19
ATE235513T1 (de) 2003-04-15
WO1999024462A2 (en) 1999-05-20
CA2309205A1 (en) 1999-05-20
AU1385699A (en) 1999-05-31
CA2301799C (en) 2007-08-07
ATE216402T1 (de) 2002-05-15
CA2301799A1 (en) 1999-05-20
AU1519799A (en) 1999-05-31
WO1999024076A2 (en) 1999-05-20
AU1312799A (en) 1999-05-31
IL135835A0 (en) 2001-05-20
JP2001522817A (ja) 2001-11-20
WO1999024074A3 (en) 1999-08-19
DE69804974D1 (de) 2002-05-23
WO1999024462A3 (en) 1999-08-26
JP2001522863A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
DE69804974D1 (de) Opioid-konjugate mit endogenen trägerproteinen
US20070082041A1 (en) Topical delivery of codrugs
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
HU912442D0 (en) Process for the production of medical preparations with continuous active agent release
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
NL8403618A (nl) Werkwijze voor het percutaan toedienen van metoclopramide.
BR0016339A (pt) Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
JP2004529886A (ja) 血液脳関門を通して鎮痛分子をベクター化することが可能なベクターに結合した前記鎮痛分子からなる化合物、及びそれらを含む医薬組成物
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
RU2026688C1 (ru) Способ получения препарата для направленной доставки противоопухолевых лекарств в раковую клетку
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
GB2095992A (en) Psycotropic drugs containing caerulein
Squibb INTROS
Li TOLERANCE TO THE EFFECTS OF Δ1‐TETRAHYDROCANNABINOL ON THE PRESSOR RESPONSES TO NORADRENALINE IN RATS
ITMI960133A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili
TH55748A (th) การใช้อินเทอร์เฟรอน-เบต้าในการบำบัดรักษาของเนื้องอกประเภทของอีวิง
JPH05221862A (ja) 坐剤用医薬組成物
RU2002100065A (ru) Применение верапамила и производных верапамила для получения лекарственных средств с действием, ингибирующим β-глюкуронидазу в ткани человека
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1007561

Country of ref document: ES